Gemcitabine-Docetaxel May Be a Feasible Alternative to BCG for High-Risk NMIBC

Investigators report their early clinical experience using intravesical sequential gemcitabine-docetaxel as first-line therapy for high-risk nonmuscle-invasive bladder cancer. Intravesical sequential gemcitabine-docetaxel may be a feasible alternative to BCG for high-risk nonmuscle-invasive bladder cancer (NMIBC).

Related Keywords

Winston Salem ,North Carolina ,United States ,Washington ,Wake Forest University ,Justin Manuel Refugia ,Vignesht Packiam ,Wake Forest University School Of Medicine ,University Of Iowa ,Society Of Urologic Oncology ,Urologic Oncology ,Wake Forest University School ,Cancers Symposium ,Iowa City ,